Literature DB >> 16265015

Primer: an evidence-based approach to prognostic markers.

Douglas G Altman1, Richard D Riley.   

Abstract

Prognostic markers can help to identify patients at different degrees of risk for specific outcomes, facilitate treatment choice, and aid patient counseling. Compared with other research designs, prognostic studies have been relatively neglected in the broad efforts to improve the quality of medical research, despite their ubiquity. Large protocol-driven, prospective studies are the ideal, with clear, unbiased reporting of the methods used and the results obtained. Unfortunately, published prognostic studies rarely meet such standards, and in this article we discuss their main problems and how they can be improved. In particular, an evidence-based approach to prognostic markers is required, as it is usually difficult to ascertain the benefit of a marker from single studies and a clear view is only likely to emerge from looking across multiple studies. Current systematic reviews and meta-analyses often fail to provide clear evidence-based answers, and rather only draw attention to the paucity of good-quality evidence. Prospectively planned pooled analyses of high-quality studies, along with general availability of individual patient data and adherence to reporting guidelines, would help alleviate many of these problems.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16265015     DOI: 10.1038/ncponc0287

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  26 in total

Review 1.  Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.

Authors:  Núria Buil-Bruna; José-María López-Picazo; Salvador Martín-Algarra; Iñaki F Trocóniz
Journal:  Oncologist       Date:  2015-12-14

2.  Diagnosis of malignant glioma: role of neuropathology.

Authors:  Daniel J Brat; Richard A Prayson; Timothy C Ryken; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

Review 3.  A systematic review of p53 as a prognostic factor of survival in squamous cell carcinoma of the four main anatomical subsites of the head and neck.

Authors:  Sankalap Tandon; Catrin Tudur-Smith; Richard D Riley; Mark T Boyd; Terence M Jones
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-02       Impact factor: 4.254

Review 4.  Biomarker studies: a call for a comprehensive biomarker study registry.

Authors:  Fabrice Andre; Lisa M McShane; Stefan Michiels; David F Ransohoff; Douglas G Altman; Jorge S Reis-Filho; Daniel F Hayes; Lajos Pusztai
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

5.  Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710.

Authors:  Eric Ojerholm; Andrew Smith; Wei-Ting Hwang; Brian C Baumann; Kai N Tucker; Seth P Lerner; Ronac Mamtani; Ben Boursi; John P Christodouleas
Journal:  Cancer       Date:  2016-10-27       Impact factor: 6.860

Review 6.  Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines.

Authors:  S Mallett; A Timmer; W Sauerbrei; D G Altman
Journal:  Br J Cancer       Date:  2009-12-08       Impact factor: 7.640

Review 7.  Publication of tumor marker research results: the necessity for complete and transparent reporting.

Authors:  Lisa M McShane; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

8.  Puerarin and betahistine treatment of vertebrobasilar ischemia vertigo: A meta-analysis of randomized controlled trials.

Authors:  Yan-Yan Chen; Wen Chen; Qing Zhang; Hui Li; Ye-Wen Zhang; Qian Kang; Y I Lan; Qing Wu
Journal:  Exp Ther Med       Date:  2016-01-18       Impact factor: 2.447

Review 9.  The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers.

Authors:  Paolo De Paoli; Chiara Pratesi; Maria Teresa Bortolin
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-25       Impact factor: 4.553

Review 10.  The role of neuropathology in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Authors:  Daniel J Brat; Timothy Charles Ryken; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2014-04-15       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.